AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Von Willebrand Disease (VWD) Epidemiology Forecasts Report 2019-2028 - ResearchAndMarkets.com

November 28, 2019

DUBLIN--(BUSINESS WIRE)--Nov 28, 2019--

The “Von Willebrand Disease (VWD) Epidemiology Forecast - 2028” report has been added to ResearchAndMarkets.com’s offering.

Von Willebrand Disease (VWD) - Epidemiology Forecast - 2028′ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.

Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 0-18 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 19-44 years reported higher diagnosed prevalence than that of people belonging to other age groups.

Von Willebrand disease (VWD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2028.

According to this research, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 2017-2028.

Among the 7MM, the highest diagnosed prevalence of von Willebrand Disease (VWD) is estimated in the United States with 11,336 diagnosed cases in 2017.

The research analysts have assessed that approximately 83% of Von Willebrand Disease patients had VWD Type 1, followed by VWD Type 2 (~11%) and Type 3 (~6%). In 2017, there were 9,422 VWD Type 1 patients, 1,250 VWD Type 2 patients, and 664 Type 3 patients in the United States.

Among the European countries, the United Kingdom had the highest diagnosed prevalent population of von Willebrand Disease (VWD) with 10,842 cases, followed by Germany which had diagnosed a prevalent population of 4,040 in 2017. On the other hand, Spain had the lowest diagnosed prevalent population of 740 in 2017.

Japan had 1,285 diagnosed prevalent cases of von Willebrand Disease in 2017.

Key Topics Covered:

1. Key Insights

2. Von Willebrand Disease (VWD): Patient Overview at a Glance

2.1. Total Patient Share (%) Distribution of VWD in 2017

2.2. Total Patient Share (%) Distribution of VWD in 2028

3. Disease Background and Overview: Von Willebrand Disease (VWD)

3.1. Introduction

3.2. Symptoms of Von Willebrand disease

3.3. Classification of Von Willebrand disease

3.4. Causes of Von Willebrand disease (VWD)

3.5. Clinical Manifestations of Von Willebrand disease (VWD)

3.6. Genetic Basis of Von Willebrand disease

3.7. Pathophysiology of Von Willebrand disease (VWD)

3.8. Diagnosis of Von Willebrand disease

3.9. Diagnostic Guidelines of Von Willebrand disease (VWD)

3.9.1. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health

3.9.2. The diagnosis of von Willebrand disease: a guideline from the UK Hemophilia Centre Doctor’s Organization

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease

5. Country Wise-Epidemiology of von Willebrand Disease

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United States

5.1.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States

5.1.4. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States

5.1.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States

5.2. EU5 Countries

5.2.1. Germany

5.2.1.1. Assumptions and Rationale

5.2.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany

5.2.1.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany

5.2.1.4. Type-Specific Diagnosed Prevalence of von Willebrand Disease in Germany

5.2.1.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany

5.2.2. France

5.2.3. Italy

5.2.4. Spain

5.2.5. United Kingdom

5.3. Japan

6. Appendix

6.1. Report Methodology

7. Capabilities

For more information about this report visit https://www.researchandmarkets.com/r/294nty

View source version on businesswire.com:https://www.businesswire.com/news/home/20191128005315/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/28/2019 05:52 AM/DISC: 11/28/2019 05:52 AM

http://www.businesswire.com/news/home/20191128005315/en